Shanler Stuart 4
4 · Aclaris Therapeutics, Inc. · Filed Feb 5, 2019
Insider Transaction Report
Form 4
Shanler Stuart
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2019-02-01+3,875→ 273,355 total - Exercise/Conversion
Restricted Stock Units
2019-02-01−3,875→ 11,625 total→ Common Stock (3,875 underlying) - Tax Payment
Common Stock
2019-02-01$6.96/sh−1,308$9,104→ 272,047 total
Footnotes (3)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
- [F3]The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.